VIP
Vasoactive Intestinal Peptide
VIP (Vasoactive Intestinal Peptide) is a healing & recovery research compound. Neuropeptide with broad anti-inflammatory and immune-balancing effects; used in CIRS/mold recovery protocols, often nasal.
VIP quick facts
| Reported research dosing (Injectable) | 50mcg-150mcg |
| Route | Subq |
| Cycle length | 4-12 Weeks |
| Frequency | 1-2x Daily Am and PM |
| Half-life | ~1-2 min systemic (longer intranasal) |
| Forms | Injectable, Nasal |
| Evidence level | Human (clinical) + protocol use |
| Other forms available | Nasal — dosed differently |
Usually the LAST step in a mold/CIRS protocol — order matters or it backfires.
How VIP works
Neuropeptide with broad anti-inflammatory and immune-balancing effects; used in CIRS/mold recovery protocols, often nasal.
Proposed benefits
Anti-inflammatory / immune modulation (CIRS and airway interest).
Where to get VIP
VIP is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
VIP reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for VIP
Graded by what exists behind each claim.
✅ Clinically validated
- Aviptadil — synthetic VIP — has been through randomized human trials, most prominently in COVID-19 respiratory failure, where results were mixed and did not support approval. It is also approved in Europe in combination with phentolamine for erectile dysfunction.
- Inhaled VIP has been trialed in pulmonary arterial hypertension and sarcoidosis with small positive signals.
📊 Correlative data
- Used intranasally in chronic inflammatory response syndrome protocols, where the published support is essentially one clinician's case series rather than controlled data. Reported experience is highly variable.
🧪 Theoretical / extrapolated
- A 28-amino-acid neuropeptide acting on VPAC1/VPAC2 receptors — it is a potent vasodilator, bronchodilator and anti-inflammatory, concentrated in the lung and gut.
- The vasodilatory potency predicts the dose-limiting effect: flushing and blood-pressure drop. It is also degraded within minutes in serum, which is why delivery route dominates whether it does anything at all.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What VIP actually does
VIP is a 28-residue peptide of the secretin/glucagon superfamily and it works through two class B G-protein-coupled receptors, VPAC1 and VPAC2. Both couple to Gs, so both do the same chemical thing: activate adenylate cyclase, raise intracellular cAMP, activate protein kinase A. One second messenger, and everything VIP is famous for comes out of it in different cells.
That single-messenger architecture is the whole problem with the drug, and it is worth being explicit about. Raise cAMP in vascular smooth muscle and you get vasodilation. Raise it in airway smooth muscle and you get bronchodilation. Raise it in a macrophage and you suppress NF-κB-driven pro-inflammatory cytokine output. The therapeutic effect people want — the third one — and the effect that limits the dose — the first one — are the same signal in different cells. There is no receptor subtype trick that separates them, because both cell types express VPAC receptors and both use cAMP. You cannot dial up the anti-inflammatory arm without dialling up the flush.
The immune-cell half does have real receptor data behind it. Burian 2010 examined VIP receptor expression on monocyte-derived and alveolar macrophages from COPD patients and found strong VPAC1 expression exceeding VPAC2, with the same pattern appearing in LPS-activated macrophages from patients and from healthy controls — that is, VPAC1 is upregulated as part of the response to a pro-inflammatory stimulus. So the receptor is genuinely there, on the right cell, and it goes up when the cell is activated. That is a mechanistically encouraging finding and it is one of the few pieces of this page that has survived every subsequent test.
And there is a human experiment nobody cites, run involuntarily. A VIPoma — a tumor secreting VIP continuously — produces a stereotyped syndrome in people: profuse secretory diarrhea, hypokalemia and achlorhydria. That is what chronically elevated VIP does to a human being, and it is the closest thing to a long-term dose-response this peptide has. It tells you which organ is most sensitive, and it is not the lung.
Cell, rodent, human — and where it stops
This page exists to show one specific pattern, and VIP displays it more cleanly than any other compound in this catalog: the effect shrinks every time the study design gets better. Follow it step by step.
Step one, eight patients, no control group, and it looked spectacular. Petkov 2003 gave vasoactive intestinal peptide to eight patients with primary pulmonary hypertension and reported a fall in mean pulmonary artery pressure, a rise in cardiac output and improved mixed venous oxygen saturation. Published in the Journal of Clinical Investigation. Uncontrolled, observational, n = 8.
Step two, twenty patients, an objective catheter, and the effect got smaller. Leuchte 2008 gave a single inhaled 100 microgram dose of aviptadil to 20 patients with pulmonary hypertension during right-heart catheterization. The effect was modest and short-lived: six of twenty showed a greater than 20% reduction in pulmonary vascular resistance, there was no sustained improvement, and systemic blood pressure was unaffected. Same indication, better instrument, uncontrolled again — and already a different-sized story.
Step three, 196 patients, randomized, placebo-controlled — and the primary endpoint was missed. Youssef 2022 randomized 196 patients with critical COVID-19 respiratory failure to three days of intravenous aviptadil or placebo. The primary endpoint — alive and free of respiratory failure at day 60 — gave an odds ratio of 1.6 (95% CI 0.86–3.11), not statistically significant. A secondary analysis, survival at day 60, gave OR 2.0 (95% CI 1.1–3.9), p = 0.035. That combination — missed primary, positive secondary — is precisely the result that justifies a confirmatory trial and precisely the result that should not be reported as a win.
Step four, 461 patients, a 2×2 factorial design, a 90-day outcome — and it was flat. Brown 2023 — TESICO — randomized 461 patients to aviptadil or placebo, with 87 also randomized to remdesivir or placebo. The primary outcome, a six-category ordinal scale at day 90, gave an odds ratio of 1.11 (95% CI 0.80–1.55, p = 0.54), and mortality was 38% on aviptadil against 36% on placebo. The accompanying comment in the same journal was titled, without hedging, a negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxemic respiratory failure Lee 2023.
The obstacle, stated exactly. Nothing failed to cross from animal to human here — every step above is human. What collapsed was the effect size, monotonically, as control improved: n = 8 uncontrolled, dramatic; n = 20 uncontrolled with an objective catheter, modest and short-lived; n = 196 randomized, primary missed; n = 461 randomized with a 90-day endpoint, odds ratio 1.11 and two percentage points of extra mortality. That sequence is what selection, regression to the mean and unblinded assessment look like when they are stripped away one layer at a time. It is not evidence that VIP does nothing — the receptor biology is real Burian 2010 and the acute hemodynamic effects are measurable — it is evidence that the size of the effect people expect was manufactured by the weakness of the early designs.
VIP pharmacokinetics — how much of it actually gets in
Route: intravenous infusion in every study that measured anything, inhaled in one, and the numbers explain why nothing else works. Domschke 1978 infused VIP into people at 0.6, 1.3 and 3.3 pmol/kg/min and measured what happened when the infusion stopped: plasma VIP fell by first-order kinetics with an average disappearance half-time of one minute. One minute. The apparent metabolic clearance rate was about 9 mL/kg/min.
And the volume of distribution is the number nobody quotes, which is a shame because it is the most informative one on the page. Domschke 1978 reports an apparent volume of distribution of approximately 14 mL/kg. Plasma volume in an adult is roughly 40 mL/kg and total body water is about 600 mL/kg. A volume of distribution of 14 mL/kg means VIP never leaves the vascular compartment — it does not distribute into tissue at all. Combine that with a one-minute half-life and the honest description of intravenous VIP is: a signal delivered to the inside of blood vessels, for about a minute. Every systemic claim for this peptide has to be compatible with that sentence.
What degrades it, and where. Chayvialle 1981 measured the same thing in dogs — half-life 1.80 ± 0.1 minutes, metabolic clearance rate 39.3 ± 5.2 mL/kg/min — and then did the experiment that localizes it: transhepatic loss of immunoreactive VIP was 72.9 ± 2.1% in a single pass, against 27.5 ± 12.5% for somatostatin. Nearly three quarters of the peptide is extracted by the liver on one pass, on top of peptidase degradation in plasma and on endothelial surfaces.
The oral barrier is therefore not a barrier, it is a wall. A 28-residue peptide meets gastric acid, pancreatic proteases and brush-border peptidases before absorption, and anything that survives goes straight into the portal vein and loses 73% of itself in the liver Chayvialle 1981. There is no oral VIP and there is no chemistry that would make one from this sequence.
Which leaves inhalation and the nose, and this is where the data thins. The one controlled inhaled exposure is a single 100 microgram dose, and its effect was modest and short-lived Leuchte 2008 — entirely consistent with the kinetics above. No intranasal VIP pharmacokinetic study has been published in a human, so the compounded nasal spray used in chronic inflammatory response protocols has no measured plasma concentration, no measured duration and no established local tissue level. Its rationale must be local nasal or direct nose-to-brain delivery, because a one-minute half-life and a 14 mL/kg volume of distribution rule out a durable systemic exposure by any route.
What would have to be true, and how you would know it was not
Four predictions. The second is the dose marker, the third is the one that cuts against every self-report about this peptide, and the fourth comes from a human syndrome rather than from a trial.
1. If the anti-inflammatory arm is being engaged, inflammatory markers should fall — and no trial has ever looked. Draw hs-CRP and TNF-alpha at baseline and at 8 weeks. The mechanism is specific and supported: VPAC1 is strongly expressed on macrophages and is upregulated by pro-inflammatory stimulation Burian 2010, and cAMP suppresses cytokine output. Remarkably, neither COVID trial reported a cytokine endpoint Youssef 2022 Brown 2023, so a handful of before-and-after draws would be new information rather than confirmation.
2. Flushing is the exposure assay, and its absence is informative. Domschke 1978 recorded cutaneous flushing and an increased pulse rate, along with rises in glucose, fatty acids and calcium, at intravenous doses of a few picomoles per kilogram per minute. Vasodilation and immune modulation are the same cAMP signal in different cells. So the falsifiable claim is simple: a dose producing no flush at all is very unlikely to be producing a systemic immune effect. Note the time and the appearance of any flush after dosing; on an intranasal product, no flush is the expected finding and it is the reason a local mechanism has to be argued rather than assumed.
3. The prediction that cuts against every account of this peptide, including the good ones: your own uncontrolled trial will show a benefit, and a blinded one will not. That is not cynicism, it is the published trajectory — dramatic at n = 8 uncontrolled Petkov 2003, modest and short-lived at n = 20 with a catheter Leuchte 2008, primary endpoint missed at n = 196 Youssef 2022, odds ratio 1.11 at n = 461 Brown 2023. The personal version of that experiment is doable: have somebody else prepare matched active and vehicle-only sprays, code them, and run two weeks on each in random order with the same daily symptom score. If the effect survives the coding, it is real and it is worth reporting; the published record predicts it will not.
4. Watch potassium, and the reason comes from the human disease rather than the drug. A VIP-secreting tumor produces secretory diarrhea and hypokalemia, which is what sustained high VIP does to a person. So run a Comprehensive Metabolic Panel (CMP) at baseline and again if dosing is escalated or prolonged, and treat new watery diarrhea as a pharmacological signal rather than as an unrelated event. At the doses used in nasal protocols this is very unlikely; at any dose producing flushing it stops being unlikely.
What nobody has tested yet
Nobody has published an intranasal VIP pharmacokinetic study in a human. Every human number in this file is intravenous Domschke 1978 or a single inhaled dose Leuchte 2008, and the route people actually use has never been measured. A plasma concentration–time curve after a standard nasal dose, in six people, would establish whether anything reaches the circulation at all — and given a one-minute half-life and a 14 mL/kg volume of distribution, it might well establish that nothing does, which would be an equally useful answer.
Nobody has measured a cytokine in a VIP trial. Two randomized controlled trials totaling 657 patients Youssef 2022 Brown 2023 were run on the premise that VIP is anti-inflammatory, and neither reported the inflammatory markers that would have shown whether the mechanism engaged. That is the single most frustrating gap in this literature: the trials cannot distinguish “the mechanism did not work” from “the drug never reached the target”, and the kinetics make the second entirely plausible.
Nobody has run a controlled trial of VIP in chronic inflammatory response syndrome, which is the use this site records. The protocol rests on one clinician’s case series. The receptor rationale is legitimate Burian 2010 and the controlled evidence is zero. Given that the same peptide has now been through two randomized trials in a different indication and returned an odds ratio of 1.11, a controlled trial in this one is both obviously needed and unlikely to be funded.
And nobody has reconciled the survival signal with the outcome. Youssef 2022 reported a doubling of the odds of survival at day 60 as a secondary endpoint, p = 0.035; Brown 2023 found 38% versus 36% mortality in a larger trial with a longer horizon. Nobody has published a pooled or individual-patient analysis asking whether a subgroup accounts for the first result. That analysis is possible with existing data and would either rescue a real effect in a definable population or close the question.
VIP — its own safety story, not its class's
The dose-limiting effect is hemodynamic and it is the mechanism, not a side effect. Domschke 1978 recorded cutaneous flushing and an increased pulse rate in people at intravenous infusion rates of 0.6 to 3.3 pmol/kg/min, alongside rises in blood glucose, fatty acids and calcium. Vasodilation is what a Gs-coupled receptor on vascular smooth muscle does; there is no formulation or receptor-subtype strategy that removes it while keeping the immune effect, because both run through cAMP.
The metabolic effects are this peptide’s own and appear on no class safety block. Glucose, free fatty acids and calcium all rose in the human infusion study Domschke 1978. A compound raising blood glucose is not what most people expect from something described as anti-inflammatory, and anybody tracking metabolic markers for another reason should know it is a documented acute effect.
The human syndrome of chronic VIP excess names the organ at risk. A VIPoma produces profuse secretory diarrhea with hypokalemia and achlorhydria. That is the gut, not the lung, and it is the best available guide to what sustained elevated VIP does to a person — more informative for chronic dosing than any of the acute trials, because those ran for three days Youssef 2022 or a single inhalation Leuchte 2008.
What the randomized trials actually showed about safety, which is reassuring and specific. In TESICO, 461 critically ill patients received aviptadil or placebo and mortality was 38% against 36% Brown 2023 — no benefit, and equally no signal of harm in the sickest population anyone will ever give this to. That is a genuinely useful safety datum and it is worth stating plainly next to the negative efficacy result.
And the risk that belongs to the product rather than the molecule. The intranasal preparations used in protocol practice are compounded: no approved product, no pharmacopoeial monograph, no published stability data for a 28-residue peptide in a nasal vehicle, and no sterility standard a buyer can check. A peptide with a one-minute circulating half-life Domschke 1978 is also one whose degradation in a bottle at room temperature is a real question that nobody has answered in print.
Sources read for this page
- Domschke S. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut 1978 · PMID 730072
- Chayvialle JA. Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs. Gut 1981 · PMID 6117506
- Burian B. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients. Peptides 2010 · PMID 20026142
- Petkov V. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003 · PMID 12727925
- Leuchte HH. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008 · PMID 18978135
- Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, Fernandez JP, Morganroth ML, Javitt JC, Jayaweera D. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.. Crit Care Med 2022 · PMID 36044317
- Brown SM. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.. Lancet Respir Med 2023 · PMID 37348524
- Lee WL. A negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxaemic respiratory failure.. Lancet Respir Med 2023 · PMID 37348523
VIP — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
From half-life and route, not a dosing trial.
VIP — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What VIP moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
If a repair peptide is doing anything systemic, inflammation is where it would plausibly show.
What to do: Worth a baseline if you are running one for a chronic issue rather than an acute injury. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Standard baseline. Nothing in this class predicts a specific abnormality — which is itself worth saying rather than inventing one.
What to do: Annual is fine unless something changes.
The honest position on this class is that the proliferation question is unresolved — anything that accelerates tissue repair is acting on pathways cancer also uses. Nobody has studied it properly either way.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside VIP
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
VIP — frequently asked questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a healing & recovery research compound. Neuropeptide with broad anti-inflammatory and immune-balancing effects; used in CIRS/mold recovery protocols, often nasal.
What dosing does the research reference for VIP?
In the research literature, VIP is referenced in the 50mcg-150mcg range, 1-2x Daily Am and PM. It is supplied as a lyophilized powder and reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. For research use only — not a recommendation for human use.
What is the half-life of VIP?
VIP has an approximate half-life of ~1-2 min systemic (longer intranasal), which is part of what determines how often it's dosed.
What forms does VIP come in?
VIP is available as: Injectable, Nasal.
What's the evidence behind VIP?
Current evidence level: Human (clinical) + protocol use. VIP is offered for research purposes only and is not an approved medicine.
VIP inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What VIP is used for
VIP appears under 3 goals in the goal router.
Related Healing & Recovery compounds
Where this goes next
VIP is the barrier arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.